title: Cytochrome P450 1B1 contributes to angiotensin II-induced hypertension and associated pathophysiology.
abstract: Hypertension is the leading cause of cardiovascular diseases, and angiotensin II is one of the major components of the mechanisms that contribute to the development of hypertension. However, the precise mechanisms for the development of hypertension are unknown. Our recent study showing that angiotensin II-induced vascular smooth muscle cell growth depends on cytochrome P450 1B1 led us to investigate its contribution to hypertension caused by this peptide. Angiotensin II was infused via miniosmotic pump into rats (150 ng/kg per minute) or mice (1000 μg/kg per day) for 13 days resulting in increased blood pressure, increased cardiac and vascular hypertrophy, increased vascular reactivity to vasoconstrictor agents, increased vascular reactive oxygen species production, and endothelial dysfunction in both species. The increase in blood pressure and associated pathophysiological changes were minimized by the cytochrome P450 1B1 inhibitor 2,3',4,5'-tetramethoxystilbene in both species and was markedly reduced in Cyp1b1(-/-) mice. These data suggest that cytochrome P450 1B1 contributes to angiotensin II-induced hypertension and associated pathophysiological changes. Moreover, 2,3',4,5'-tetramethoxystilbene, which prevents both cytochrome P450 1B1-dependent and -independent components of angiotensin II-induced hypertension and inhibits associated pathophysiological changes could be clinically useful in the treatment of hypertension and associated cardiovascular and inflammatory diseases.
authors.affiliation: Department of Pharmacology, College of Medicine, University of Tennessee Health Science Center, Memphis, Tenn 38163, USA.
authors.forename: Brett L
authors.initials: BL
authors.lastname: Jennings
authors.forename: Seyhan
authors.initials: S
authors.lastname: Sahan-Firat
authors.forename: Anne M
authors.initials: AM
authors.lastname: Estes
authors.forename: Kanak
authors.initials: K
authors.lastname: Das
authors.forename: Nasreen
authors.initials: N
authors.lastname: Farjana
authors.forename: Xiao R
authors.initials: XR
authors.lastname: Fang
authors.forename: Frank J
authors.initials: FJ
authors.lastname: Gonzalez
authors.forename: Kafait U
authors.initials: KU
authors.lastname: Malik
mesh_terms: D000804:Angiotensin II / Q000008:administration & dosage / Q000633:toxicity*; D000818:Animals; D001011:Aorta / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D001189:Aryl Hydrocarbon Hydroxylases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D001794:Blood Pressure / Q000187:drug effects* / Q000502:physiology; D015153:Blotting, Western; D006332:Cardiomegaly / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control; D065633:Cytochrome P-450 CYP1B1; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology; D006973:Hypertension / Q000139:chemically induced / Q000503:physiopathology* / Q000517:prevention & control; D007262:Infusions, Intravenous; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D019255:NADPH Oxidases / Q000378:metabolism; D009929:Organ Size; D051381:Rats; D017207:Rats, Sprague-Dawley; D017382:Reactive Oxygen Species / Q000378:metabolism; D013267:Stilbenes / Q000008:administration & dosage / Q000494:pharmacology; D014662:Vasoconstrictor Agents / Q000494:pharmacology / Q000633:toxicity
chemical_list: C440850:2,4,3',5'-tetramethoxystilbene; D017382:Reactive Oxygen Species; D013267:Stilbenes; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D001189:Aryl Hydrocarbon Hydroxylases; C585498:Cyp1b1 protein, mouse; C585499:Cyp1b1 protein, rat; D065633:Cytochrome P-450 CYP1B1; D019255:NADPH Oxidases; D020928:Mitogen-Activated Protein Kinases
references.citation: Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):139-46
references.pmid: 10067811
references.citation: Kidney Int. 2007 Jun;71(11):1105-15
references.pmid: 17361113
references.citation: J Pharmacol Exp Ther. 2009 Feb;328(2):478-86
references.pmid: 18984652
references.citation: J Cardiovasc Pharmacol. 1996 Nov;28(5):703-11
references.pmid: 8945685
references.citation: Mol Pathol. 1998 Jun;51(3):138-42
references.pmid: 9850336
references.citation: Mutagenesis. 2008 Nov;23(6):457-63
references.pmid: 18583386
references.citation: Cardiovasc Res. 2009 Mar 1;81(4):669-77
references.pmid: 19126602
references.citation: Hypertension. 1998 Jan;31(1 Pt 2):194-200
references.pmid: 9453302
references.citation: Am J Physiol. 1990 Dec;259(6 Pt 2):H1774-80
references.pmid: 2124426
references.citation: J Hypertens. 2004 Jun;22(6):1141-9
references.pmid: 15167449
references.citation: Cell Physiol Biochem. 2007;19(1-4):121-8
references.pmid: 17310106
references.citation: Cancer Res. 2001 Nov 15;61(22):8164-70
references.pmid: 11719446
references.citation: Nat Rev Drug Discov. 2009 Oct;8(10):794-805
references.pmid: 19794443
references.citation: Am J Physiol Regul Integr Comp Physiol. 2002 Jul;283(1):R60-8
references.pmid: 12069931
references.citation: Drug Metab Rev. 2006;38(3):411-50
references.pmid: 16877260
references.citation: Hypertension. 2000 Oct;36(4):604-9
references.pmid: 11040243
references.citation: Hypertension. 1994 Jan;23(1 Suppl):I142-7
references.pmid: 8282345
references.citation: Pharmacol Rev. 2007 Sep;59(3):251-87
references.pmid: 17878513
references.citation: Cancer Res. 1996 Jul 1;56(13):2979-84
references.pmid: 8674051
references.citation: J Clin Invest. 1996 Apr 15;97(8):1916-23
references.pmid: 8621776
references.citation: Circ Res. 2005 Apr 29;96(8):818-22
references.pmid: 15860762
references.citation: Hypertension. 2010 Jun;55(6):1461-7
references.pmid: 20439821
references.citation: Am J Physiol Heart Circ Physiol. 2001 Jul;281(1):H30-9
references.pmid: 11406465
references.citation: J Biol Chem. 2002 Mar 22;277(12):9920-8
references.pmid: 11786549
references.citation: Annu Rev Pharmacol Toxicol. 1981;21:479-509
references.pmid: 7016014
references.citation: Atherosclerosis. 1982 Sep;44(3):339-42
references.pmid: 6816252
references.citation: Arterioscler Thromb Vasc Biol. 2000 Apr;20(4):940-8
references.pmid: 10764657
references.citation: J Pharmacol Exp Ther. 1998 Jan;284(1):388-98
references.pmid: 9435202
references.citation: In Vitro Cell Dev Biol Anim. 1998 Oct;34(9):671-3
references.pmid: 9794216
references.citation: Physiol Rev. 2002 Jan;82(1):131-85
references.pmid: 11773611
references.citation: Curr Opin Nephrol Hypertens. 2001 Mar;10(2):231-7
references.pmid: 11224699
references.citation: J Cardiovasc Pharmacol. 2007 Jun;49(6):362-8
references.pmid: 17577100
references.citation: Hypertension. 2001 Dec 1;38(6):1311-5
references.pmid: 11751709
references.citation: J Exp Med. 2007 Oct 1;204(10):2449-60
references.pmid: 17875676
references.citation: Circ Res. 2002 Nov 29;91(11):1038-45
references.pmid: 12456490
references.citation: Cardiovasc Res. 2006 Sep 1;71(4):794-802
references.pmid: 16822492
references.citation: Nat Med. 2010 Feb;16(2):183-90
references.pmid: 20098430
references.citation: J Clin Invest. 2005 Apr;115(4):1092-9
references.pmid: 15841186
references.citation: Drug Metab Dispos. 2004 Aug;32(8):840-7
references.pmid: 15258110
references.citation: Hypertension. 1998 Jan;31(1 Pt 2):242-7
references.pmid: 9453310
references.citation: Cardiovasc Res. 2002 Mar;53(4):1002-9
references.pmid: 11922910
references.citation: Circ Res. 1994 Jun;74(6):1141-8
references.pmid: 8187280
references.citation: Cancer Sci. 2004 Jan;95(1):1-6
references.pmid: 14720319
references.citation: Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9776-81
references.pmid: 8790407